Biogen Inc. BIIB
We take great care to ensure that the data presented and summarized in this overview for BIOGEN INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BIIB
View all-
Vanguard Group Inc Valley Forge, PA16.7MShares$1.99 Billion0.05% of portfolio
-
Primecap Management CO Pasadena, CA16MShares$1.9 Billion1.94% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$1.72 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.4MShares$878 Million0.05% of portfolio
-
Geode Capital Management, LLC Boston, MA3.7MShares$438 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.1MShares$368 Million0.29% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.67MShares$316 Million1.01% of portfolio
-
Norges Bank Oslo, Q82.33MShares$276 Million0.05% of portfolio
-
Invesco Ltd. Atlanta, GA2.13MShares$252 Million0.06% of portfolio
-
Jpmorgan Chase & CO New York, NY2.1MShares$249 Million0.03% of portfolio
Latest Institutional Activity in BIIB
Top Purchases
Top Sells
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at BIIB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 07
2025
|
Stephen A Sherwin Director |
SELL
Open market or private sale
|
Direct |
8,760
-43.63%
|
$1,314,000
$150.02 P/Share
|
|
Feb 10
2025
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
245
-2.97%
|
$34,790
$142.54 P/Share
|
|
Feb 10
2025
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
834
+9.17%
|
-
|
|
Feb 10
2025
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,371
-5.33%
|
$194,682
$142.54 P/Share
|
|
Feb 10
2025
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,257
+11.24%
|
-
|
|
Feb 10
2025
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
670
-4.55%
|
$95,140
$142.54 P/Share
|
|
Feb 10
2025
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
2,272
+13.37%
|
-
|
|
Feb 10
2025
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
357
-3.79%
|
$50,694
$142.54 P/Share
|
|
Feb 10
2025
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,212
+11.4%
|
-
|
|
Feb 10
2025
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
445
-4.95%
|
$63,190
$142.54 P/Share
|
|
Feb 10
2025
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
1,515
+14.41%
|
-
|
|
Feb 10
2025
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
807
-2.18%
|
$114,594
$142.54 P/Share
|
|
Feb 10
2025
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,575
+6.49%
|
-
|
|
Feb 10
2025
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
634
-3.48%
|
$90,028
$142.54 P/Share
|
|
Feb 10
2025
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
2,159
+10.59%
|
-
|
|
Feb 07
2025
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
3,844
+20.34%
|
-
|
|
Feb 07
2025
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,165
-8.42%
|
$164,265
$141.35 P/Share
|
|
Feb 07
2025
|
Christopher Viehbacher President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,201
-20.0%
|
$451,341
$141.35 P/Share
|
|
Feb 07
2025
|
Christopher Viehbacher President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,008
+36.01%
|
-
|
|
Feb 07
2025
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,502
-3.35%
|
$211,782
$141.35 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 11.2K shares |
|---|---|
| Exercise of conversion of derivative security | 55.6K shares |
| Bona fide gift | 20.1K shares |
| Payment of exercise price or tax liability | 18.3K shares |
|---|---|
| Open market or private sale | 9.3K shares |
| Bona fide gift | 20.1K shares |